AR and neoplasm: We found that metformin treatment in a clinically relevant dose of ~ 70 μM [49, 50] decreased size, weight, and tumor volume in AR/STAT3 expressing 22Rv1 cells but was ineffective for PC3 xenografts, which lack STAT3 (Fig. 4B-D).